Lumos Pharma — NewLink Genetics — Q1 2016 Earnings Presentation
10 slides from Lumos Pharma's earnings presentation, Apr 29, 2016
Slide 1: First Quarter 2016 Operational and Financial Results
First Quarter 2016 Operational and Financial Results Nasdaq: NLNK April 29, 2016
Slide 2: Agenda
Agenda 2 Introduction Jack Henneman, Executive Vice President & CFO 2016 Priorities Charles J. Link, Jr., M.D., Chairman, CEO & CSO IDO Pathway Inhibitor Programs Update Nicholas N. Vahanian, M.D., President & CMO GDC-0919 Update Dr. Vahanian First Quarter 2016 Financial Results Mr. Hennem
Slide 3: Safe Harbor Statement
Safe Harbor Statement This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Priv
Slide 4: NewLink Genetics Programs
4 NewLink Genetics Programs HyperAcute® Cellular Immunotherapies Pancreatic NSCLC Advanced Melanoma Prostate Kidney IDO Pathway Inhibitors Breast Prostate Pancreatic Advanced Melanoma Refractory Malignant Brain Tumors Solid Tumors Infectious Diseases Ebola vaccine program Zika
Slide 5: 2016 Business Priorities
2016 Business Priorities 5 Charles J. Link, Jr., M.D., Chairman, CEO, & CSO HyperAcute Cellular Immunotherapy IMPRESS Phase 3 – Report on top-line results in 2Q-2016 – Execute on regulatory strategy with FDA – Continue U.S. commercialization planning – Explore partnering strategy outside U.S. Hy
Slide 6: IDO Pathway Inhibitor Programs Update
IDO Pathway Inhibitor Programs Update 6 Nicholas Vahanian, M.D., President & Chief Medical Officer IDO Pathway Inhibitors Provide clinical update at ASCO in June 2016 on the following trials: – Interim data update from a Phase 2 trial with a target enrollment of 80 patients evaluating the addition
Slide 7: IDO Pathway Inhibitor Programs Update
IDO Pathway Inhibitor Programs Update 7 Nicholas Vahanian, M.D., President & Chief Medical Officer IDO Pathway Inhibitors Additional data updates expected in Q2 2016 include: – Mid-trial from a Phase 2 trial with a target enrollment of 132 patients of indoximod in combination with temozolomide for
Slide 8: GDC-0919 Clinical Update
GDC-0919 Clinical Update 8 Nicholas Vahanian, M.D., President & Chief Medical Officer GDC-0919: Partnered with Genentech Genentech to present an update on GDC-0919 at ESMO in October
Slide 9: First Quarter 2016 Financial Results
First Quarter 2016 Financial Results 9 Jack Henneman, EVP and Chief Financial Officer Strong Capital Position Stable and reliable cash position - $178M at Q1 2016 / $197.8M at YE 2015 Goal and expectation to finish 2016 with two years of cash-on-hand Multiple Value Drivers Increased Investment
Slide 10: Brewin
Brewin A